WHITE PAPER ࢪ࠾ࡅࡿ་⸆ရ⏘ᴗࡢ ᑗ᮶ྥࡅࡓᆅẆኚື Amar Kureishi ࢡࣥࢱࣝࢬࠉࢪᆅ༊ࢳ࣮ࣇ࣓ࢹ࢝ࣝ࢜ࣇࢧ࣮ ව་⸆ရ㛤Ⓨ㈐௵⪅ せ᪨ ་⸆ရ⏘ᴗ䛿䛭䛾ᑗ᮶䛻ၥ㢟䜢ᢪ䛘䛶䛚䜚䚸ᒱ㊰䛻❧䛯䛥䜜䛶䛔䜛䚹䛣䛾ၥ㢟䛿䚸་⸆ရ⏘ᴗ䛜ᙧᡂ 䛥䜜䜛㐣⛬䛷⏕䛨䛯῝้䛺ᵓ㐀Ḟ㝗䛻㉳ᅉ䛧䛶䛚䜚䚸㠀ᖖ䛻᰿῝䛔䜒䛾䛷䛒䜛䚹㐍ⓗ䛺㠉᪂䛷䛿䚸䜒 䛿䜔ᑐฎ䛷䛝䛺䛔䚹་⸆ရ⏘ᴗ䛻䛿ᢤᮏⓗ䛺ኚ㠉䛜ᚲせ䛷䛒䜚䚸䜰䝆䜰䛻䛿䛣䛖䛧䛯యไ䜢ᵓ⠏䛩 䜛䛯䜑䛾ẚ㢮䛺䛝ᶵ䛜Ꮡᅾ䛩䜛䚹ኚ㠉䛾䛯䜑䛾ᚲせ᮲௳䛿䚸〇⸆ᴗ䛜䚸䜰䝆䜰䛾⯆㝯䜎䛯䛿⯆ 䜢ṇ䛧䛟ㄆ㆑䛩䜛䛣䛸䚸䛥䜙䛻䚸ᆅᇦ䜢⌮ゎ䛧䠄㼡㼚㼐㼑㼞㼟㼠㼍㼚㼐㼕㼚㼓㻌㼘㼛㼏㼍㼘䠅䚸ᆅᇦ䛷⪃䛘䠄㼠㼔㼕㼚㼗㼕㼚㼓㻌㼘㼛㼏㼍㼘䠅䚸ᆅᇦ 䛻᰿ᕪ䛩䠄㼎㼑㼕㼚㼓㻌㼘㼛㼏㼍㼘䠅䛸䛔䛖㞴㢟䜢ඞ᭹䛩䜛䛣䛸䛷䛒䜛䚹་⸆ရ㛤Ⓨᴗົཷクᶵ㛵䠄㻯㻾㻻䠅䛿䚸⏘ᴗᶓ ᩿ⓗ䛺ど㔝䜢ᣢ䛳䛶䛚䜚䚸䛂㌴㍯䛸䝇䝫䞊䜽䛃䛸䛔䛖᪂䛧䛔䝟䞊䝖䝘䞊䝅䝑䝥䝰䝕䝹䛻䛚䛔䛶୰ᚰⓗᙺ 䜢ᢸ䛳䛶䛔䜛䛣䛸䜢⮬ぬ䛧䚸䜰䝆䜰䛻䛚䛡䜛༢䛺䜛䝃䞊䝡䝇ᥦ౪⪅䛛䜙་⒪ኚ㠉䛾ᑟⓗ䛺ᐇ⾜⪅䜈䛸 㐍䛩䜛ᚲせ䛜䛒䜛䚹 ࡣࡌࡵ ୡ⏺䛿⌧ᅾ䚸䜾䝻䞊䝞䝹⤒῭䚸ᆅᨻᏛⓗ䝟䝽䞊䝅䝣䝖䚸䛚䜘䜃Ẽೃኚື䛾㠃䛷ᒱ㊰䛻❧䛯䛥䜜䛶䛚䜚䚸་⸆ ရ⏘ᴗ䜒䜎䛯ṇᛕሙ䜢㏄䛘䛶䛔䜛䚹◊✲㛤Ⓨ䛻䛚䛡䜛⏕⏘ᛶ䛾ప䛥䛸䛭䛾䝁䝇䝖䛾ቑຍ䚸౯᱁ᘬୗ䛢ᅽຊ䚸 䛚䜘䜃≉チษ䜜䛺䛹䛾᰿ᮏⓗ䛺ၥ㢟䛜Ꮡᅾ䛧䛶䛚䜚䚸་⸆ရᴗ⏺䛿✚ᴟⓗ䛻䚸ሙྜ䛻䜘䛳䛶䛿ᠱ䛻䚸⮬ ᕫᨵ㠉䜢ヨ䜏䛶䛔䜛䚹ྠᴗ⏺䛿䚸᪂⯆ᕷሙ䛷䛾ᚋⓎ་⸆ရ䜔ከΰྜ⸆䚸ᚋ㻡ᖺ㛫䛷≉チ䛜ษ䜜䜛ᩘ ᑡ䛺䛔䝤䝻䝑䜽䝞䝇䝍䞊䛜ฟ䛩䜛㻡㻜㻜൨⡿䝗䝹ᕷሙ䛾୍㒊⋓ᚓ䜢┠ᣦ䛧䛯䜾䝻䞊䝞䝹ᚋⓎ་⸆ရ䝥䝻䜾䝷 䝮䛺䛹䚸ᵝ䚻䛺ᡓ␎䜢䛸䛳䛶䛔䜛䚹䜎䛯ᴗ㈙䜔ྜే䛻䜘䜛᪂䛧䛔䝟䞊䝖䝘䞊䝅䝑䝥䜔䜰䝷䜲䜰䞁䝇䛜䚸䜋䜌 ẖ᪥䛾䜘䛖䛻Ⓨ⾲䛥䜜䛶䛔䜛䚹㠀ᖖ䛻ಖᏲⓗ䛷ᐁⓗ䛺ᢎㄆᡭ⥆䛝䛾䛯䜑䛻㠉᪂䛜㜼ᐖ䛥䜜䛶䛔䜛䛸ゝ䜟 䜜䛶䛚䜚䚸䜎䛯௬⸆䛻㛵䛧䛶䛿ከᵝ䛷㦫␗ⓗ䛺䜲䞁䝅䝸䝁䜔㛤䛛䜜䛯㠉᪂ⓗ䝰䝕䝹䛻䛴䛔䛶䛾㆟ㄽ䛜 ┒䜣䛻⾜䜟䜜䛶䛔䜛䚹㻞㻜㻝㻝ᖺ䛿䚸⡿ᅜ䛷ᢎㄆ䛥䜜䛯᪂⸆⏦ㄳ䛿㻟㻡௳䛸㇏స䛾ᖺ䛷䛒䜚䚸ᴗ⏺䛾᪉ྥ㌿ 䛾฿᮶䜢࿌䛢䛯䛛䛸䜒ᛮ䜟䜜䛯䛜䚸➨䊠┦䛚䜘䜃➨䊡┦䛾䝟䜲䝥䝷䜲䞁䛜㐣ཤ᭱ప䛾≧ែ䛸䛺䛳䛯䛣䛸䛷Ẽ 㐠䛿పୗ䛧䛶䛧䜎䛳䛯䚹⤖ᯝ䛸䛧䛶䚸᪉ྥ㌿䛜ぢ䜙䜜䛯䛾䛿㻾㻒㻰䛾⏕⏘ᛶ䛷䛿䛺䛟㻲㻰㻭䛾⸆つไ䛷䛿 䛺䛔䛛䚸䛸ぢ䜛ᑓ㛛ᐙ䜒䛔䜛㻝 䚹 䛣䛖䛧䛯ᴗ⏺䛾ື䛝䛻䛴䛔䛶䚸䛂ᴗ⏺䛿᪂㢼䜢྿䛝㎸䜣䛷䛔䜛䛾䛛䚸䛭䜜䛸䜒⇵䛜⇞䛘ᑾ䛝䜛๓䛾୍▐䛾䜖 䜙䜑䛝䛺䛾䛛㻫䛃䛸䛔䛖ၥ䛜⏕䛨䜛䚹⪥㞀䜚䛺㡢䛿ሗ䜢ఏ䛘䜛䜘䜚䜒ΰ䜢ᣍ䛝䛛䛽䛪䚸᭱⤊ⓗ䛻䛿㌟㏆䛻 䛒䜛ᇶᮏⓗ䛺ㄢ㢟䛛䜙⚾䛯䛱䛾ὀព䜢䛭䜙䛩䛣䛸䛻䛺䜛䚹ᮏ᭩䛿ᖺ䛾䛂䜰䝆䜰㻦㻌ᡓ␎ⓗ་⸆ရ㛤Ⓨ䛾᪂䛧 䛔䝣䝻䞁䝔䜱䜰䛃㻞䚷䛾⥆⦅䛸䛧䛶グ䛧䛯䜒䛾䛷䛒䜚䚸௨ୗ䛾Ⅼ䜢᳨ウ䛧䛯䚹㻌 㻌 㻌 㻌 㻝㻚㻌⌧ᅾ䛾་⸆ရ⏘ᴗ䜢ᨭ䛘䛶䛔䜛ᵓ㐀䝥䝺䞊䝖䛸᩿ᒙ⥺ 㻞㻚㻌䜰䝆䜰䜔䛾᪂⯆ᕷሙ䛾㔜せᛶ䛸䚸᪂⯆ᕷሙᡓ␎䛾ᡂຌ䛻ᚲせ䛺㻟ཎ๎ 㻟㻚㻌䜰䝆䜰䛾ྎ㢌䛜་⸆ရ⏘ᴗ䛾ᢤᮏⓗኚ㠉䛻䜒䛯䜙䛩ᶵ ᦂࢀືࡃᇶ┙ኚࡀᚲせ࡞≧ἣ ་⸆ရᴗ⏺䛜ᢪ䛘䜛ၥ㢟䛻ྲྀ䜚ྜ䜟䛺䛔ே䛜䛔䜛䛸䛩䜜䜀䚸䛭䜜䛿་⸆ရ⏘ᴗ⮬య䛾」㞧䛥䜔◊✲㛤Ⓨ 䛻ෆᅾ䛩䜛⊂≉䛺ㄢ㢟䜢ㄆ㆑䛷䛝䛶䛔䜛䛸䛿ゝ䛘䛺䛔䚹䛭䜒䛭䜒䚸⸆䛛䜙᪂⸆䛾ୖᕷ䜎䛷䛾〇ရ㛤Ⓨ䝃䜲 䜽䝹䛿䚸⯟✵Ᏹᐂ䜔䜶䝺䜽䝖䝻䝙䜽䝇䛸䛔䛳䛯䛾」ྜ⏘ᴗ䛾〇ရ㛤Ⓨᮇ㛫䛸ẚ䜉䛶䜒㠀ᖖ䛻㛗䛔䚹་⸆ရ 䛜⸆䛛䜙⮫ᗋ㛤Ⓨẁ㝵䜢⤒䛶䚸⸆ᢎㄆ䜢ཷ䛡䚸᭱⤊ⓗ䛻ୖᕷ䛻⮳䜛䜎䛷䛻䛿㻤䡚㻝㻞ᖺ䜢せ䛩䜛䚹୍᪉䚸 䜶䜰䝞䝇㻟㻤㻜䛷䛿䚸ᵓẁ㝵䛛䜙୍ྕᶵ䛾⣡ရ䜎䛷䛻せ䛧䛯ᮇ㛫䛿㻢ᖺᮍ‶䛷䛒䛳䛯䚹㼕㻼㼛㼐䛾ሙྜ䛿䛥䜙䛻 ▷䛟䚸䜰䝑䝥䝹♫䛿䜰䜲䝕䜱䜰╔ᚋ㻝ᖺ௨ෆ䛻〇ရ䜢㈍䛧䛯䚹་⸆ရ䛷䛿䚸㛤Ⓨᮇ㛫䛜㛗ᮇ䛩䜛䛣䛸䛷䚸 㛤Ⓨ䛿」㞧䛧䚸㈝⏝䜒⭾䜙䜏䚸ᑗ᮶䛾☜ᐇᛶ䛜㧗䜎䜛䚹䜎䛯䚸㛤Ⓨᮇ㛫䛜㛗ᮇ䛩䜛䛣䛸䛷䚸〇⸆ᴗ 䛿㻝㻜ᖺ௨ୖ䜒ඛ䛾ᑗ᮶䜢ண 䛩䜛ᚲせ䛻㏕䜙䜜䜛䛜䚸䛣䜜䛿ᐇ㉁ⓗ䛻ྍ⬟䛷䛒䜛䚹㻝㻜ᖺ䜒䛒䜜䜀ୡ⏺ 䛿䛝䛟ኚ䛩䜛ྍ⬟ᛶ䛜䛒䜚䚸ᐇ㝿䛻䛭䛖䛧䛯䛣䛸䛿䛧䜀䛧䜀㉳䛣䜛䚹᪂⸆䛾㐺ᛂ䛸䛺䜛ᝈ䛾⟶⌮䚸ᕷሙ Ⓨᒎ䛸㏆௦䛻క䛔䚸䜰䝆䜰䛾ྛᅜ䛿⮬ᅜ䛾≉ᚩⓗ䛛䛴ᩥⓗ䛺䜰䜲䝕䞁䝔 䜱䝔䜱䜢䜘䜚㩭᫂䛻♧䛩䛿䛪䛷䛒䜛䚹䛔䛛䛺䜛⏘ᴗ䛻䛚䛔䛶䜒䚸䜰䝆䜰䛷ᡂຌ䛧 䛯䛔䛸⪃䛘䛶䛔䜛ከᅜ⡠ᴗ䛿䚸䛂ᆅᇦ䛻᰿ᕪ䛩䛃䛣䛸䜢Ꮫ䜃䚸౯್䜢㐀䛩䜛 ᙜᆅ䛾ᴗᶵ䜢ㄆ㆑䛧䚸䛣䜜䜢ά⏝䛧䛶䛔䛟ᚲせ䛜䛒䜛䚹 1 Herper M. The Truth About 2011’s New Drug Approvals. Forbes. 18 July 2011. Available from: http://www.forbes.com/ sites/matthewherper/2011/07/18/the-truth-about-2011s-new-drug-approvals/ 2 Kureishi A. Asia: A New Frontier for Strategic Drug Development. Quintiles. 8 March 2011. Available from: http://www. quintiles.com/information-library/white-papers/asia-new-frontier-strategic-drug-development/ www.quintiles.com 2 Figure 1: The Current Development Model S TAGE 2 S TAGE 3 S TAGE 4 Drug Discovery Preclinical Clinical Trials FDA Review 250 COMPOUNDS PHA SE 3 1000-5000 Volunteers 5 COMPOUNDS PHA SE 2 100-500 Volunteers 7 Years 6.5 Years NDA Submitted 10,0 0 0 COMPOUNDS IND Submitted PHA SE 1 20-100 Volunteers 1 FDA APPROVED DRUG S TAGE 1 1.5 Years ➇த⎔ቃ䚸ൾ㑏ไᗘ䜔ᕷሙຊᏛ䚸䝸䝇䜽䞉䝧䝛䝣䜱䝑䝖䞉䝥䝻䝣䜯䜲䝹䛻㛵䛩䜛⾜ᨻ䛾ᮇᚅ䛺䛹䛿䚸䛔䛛䛺䜛་ ⸆ရ䛻䛚䛔䛶䜒䚸㻝㻜ᖺ䛷䛝䛟ኚ䛩䜛ྍ⬟ᛶ䛜䛒䜛䠄ᅗ㻝䠉◊✲㛤Ⓨ䝃䜲䜽䝹䠅䚹 E XPENDITURE PER DRUG (in Millions, measured in 2000 dollars) ṇ⌧ᅾ౯್䠄㻺㻼㼂䠅䛿䚸䛒䜛䝥䝻䝆䜵䜽䝖䛻ᑐ䛩䜛⌧ᅾ䛾ᢞ㈨䛜䚸ᑗ᮶ᚓ䜙䜜䜛ண ┈䛻ᇶ䛵䛔䛶ṇᙜ 䛷䛝䜛䛛ྰ䛛䜢᳨ウ䛩䜛㝿䛻⏝䛔䜙䜜䜛䚹ᢞ㈨䛻䜘䜛ᑗ᮶䛾ṇ䜻䝱䝑䝅䝳䝣䝻䞊䛾⌧ᅾ౯್䛛䜙䚸ᙜึ ᢞ㈨㢠䜢ῶ䛨䛯䜒䛾䛸䛧䛶ᐃ⩏䛥䜜䛶䛚䜚䚸ྍ⬟ᛶ䛾䛒䜛་⸆ရ䛾䛔䛪䜜䛻ᢞ㈨౯್䛜䛒䜛䛛䜢ホ౯䛩䜛 ၏୍䛾ᐈほⓗᡭἲ䛷䛒䜛䚹䛧䛛䛧䚸ᐇ㝿䛻䛣䛾᪉ἲ䜢⏝䛔䛶䛔䜛ே䛿ⓙ䚸㻺㻼㼂䛾⟬ฟ䛿䚸ᐈほᛶ䛜ప䛟䚸᳨ ド⬟䛺ከ䛟䛾௬ᐃ䛻ᇶ䛵䛔䛶䛔䜛䛸ドゝ䛩䜛䚹㻺㻼㼂䛿䚸〇ရ㛤Ⓨᮇ㛫䛜▷ᮇ㛫䛷䛒䜛䛾⏘ᴗ䛷䛿᭷ ຠ䛛䜒䛧䜜䛺䛔䛜䚸ண 䛥䜜䜛௬ᐃ䛜㐲䛔ᑗ᮶䛾䜒䛾䛻䛺䜜䜀䛺䜛䜋䛹䚸ㄗᕪ䜢ྵ䜣䛰ၥ㢟䛾ከ䛔௬ᐃ䛸 䛺䜛䚹ṧᛕ䛺䛣䛸䛻་⸆ရᴗ⏺䛿䚸䛭䛾ពᛮỴᐃ䜢ᨭ䛘䜛᫂☜䛺௦᭰ᡭẁ䜢ᣢ䛳䛶䛚䜙䛪䚸〇ရ㛤Ⓨ䝟䜲䝥 䝷䜲䞁䛾ඃඛ㡰䜢䛡䜛㝿䛻䛿䚸⤒Ⴀ⏬㒊㛛䛛䜙ฟ䛥䜜䜛㻺㻼㼂䛾⤖ᯝ䜢䛒䛯䛛䜒䝝䞊䝗䝃䜲䜶䞁䝇䛾䜘 䛖䛻ᢅ䛳䛶䛔䜛䚹 Figure 2: Expenditures per Rx Drug 㻺㻼㼂䛻⏕᮶ⓗ䛻ഛ䜟䛳䛯ᙅⅬ䛿䛥䛶䛚䛝䚸䛭䜒 1000 CURRENT COS T: 䛭䜒㻺㻼㼂䜢⏝䛔䛶ホ౯䛧䛯་⸆ရ䛾◊✲㛤Ⓨ $1.2 Billion per NME ᢞ㈨䛜ᐇ㝿䛻ᡂຌ䛧䛶䛔䜛䛾䛛ྰ䛛䜒ၥ㢟䛷 $802 䛒䜛䚹䝗䜲䝒㖟⾜䛜㻞㻜㻝㻝ᖺ䛻Ⓨ⾲䛧䛯ሗ࿌᭩䛷 800 䛿䚸Ḣᕞ䛾ᡭ〇⸆ᴗୖ㻣♫䛜ศᯒ䛾ᑐ ㇟䛸䛺䛳䛶䛚䜚䚸䜎䛥䛻䛣䛾ၥ㢟䛻䛴䛔䛶ၥ䜢 ᢞ䛢䛛䛡䛶䛔䜛䚹㻟䚷䛭䜜䛻䜘䜛䛸䚸䛣䜜䜙䛾〇⸆ 600 ᴗ䛜㻞㻜㻜㻣ᖺ䛛䜙㻞㻜㻝㻝ᖺ䛻䛛䛡䛶ୖᕷ䛧䛯〇 ရ䛾㻺㻼㼂䛾ྜィ㢠䛸䚸◊✲㛤Ⓨᢞ㈨㢠䛾ྜィ 400 㢠䛸䜢ẚ㍑䛧䛯䛸䛣䜝䚸◊✲㛤Ⓨᢞ㈨㢠㻝㻢㻝㻜൨ $318 ⡿䝗䝹䛻ᑐ䛧䚸㻺㻼㼂䛾⣼✚㢠䛿䜟䛪䛛㻤㻢㻜൨⡿ 䝗䝹䛷䛒䛳䛯䚹ᐇ䚸䛣䛾ᮇ㛫୰䛻ᢞ㈨䛧䛯◊✲ $138 200 㛤Ⓨ㈝⏝䜘䜚䚸ୖᕷ䛧䛯ၟရ䛾㻺㻼㼂䛾᪉䛜㧗䛛 䛳䛯〇⸆ᴗ䛿䚸㻣♫୰㻝♫䛾䜏䛷䛒䛳䛯䚹䠄ᅗ㻟 䚹㻲㼀䜘䜚䠅 0 1975 1987 2000 〇ရ㛤Ⓨ䝃䜲䜽䝹䛾㛗ᮇၥ㢟䛚䜘䜃ᢞ㈨䛻 ᑐ䛩䜛ᑗ᮶┈䛾☜ᐇᛶ䛜䜎䛩䜎䛩ቑ㛗䛥䜜䜛䛣䛸䛷䚸་⸆ရ䛾◊✲㛤Ⓨ䛜ᴟ䜑䛶㧗㢠䛸䛺䛳䛶䛔䜛䛣 䛸䛿ᐇ䛷䛒䜛䚹ከᅜ⡠䛾〇⸆ᴗ䛻䛚䛡䜛ᆺⓗ䛺◊✲㛤Ⓨண⟬䛿䚸⥲┈䛾㻝㻡䡚㻞㻜䠂䛷䛒䜛䚹ẚ㍑ 3 Parkes R, Race T, Clark M. R&D productivity: Delivering sufficient value to support post-cliff growth. Deutsche Bank. 1 September 2011.www.quintiles.com/information-library/white-papers/asia-new-frontier-strategic-drug-development/ 3 www.quintiles.com Figure 3: R&D Expenditures and Yields S TRUGGLING TO GAIN RE T URNS ON INVE S TMENT (20 07-11) Roche Sanofi Novartis GSK AstraZeneca Bayer Novo Nordisk $22.5B $10.6B $7.2B $7.1B $6.6B $3.4B 3 3 1 R&D Spend $35.1B $28.7B $28.7B $28.3B Net Present Value of New Drug Approvals $6.0B $10.2B $37.7B $19.6B New Drug Approvals 2 5 15 16 From The Financial Times, 17 Oct. 2011 䜢ᣲ䛢䜛䛸䚸⯟✵Ᏹᐂ䜔䜶䝺䜽䝖䝻䝙䜽䝇⏘ᴗ䛻䛚䛡䜛◊✲㛤Ⓨண⟬䛿䚸⥲┈䛾㻠䡚㻡䠂䛷䛒䜛䠄ᅗ㻠䠅䚹䛥 䜙䛻䚸་⸆ရ䛾◊✲㛤Ⓨண⟬䛷᭱䜒㧗䛔ྜ䜢༨䜑䜛䛾䛿䚸⸆ᢎㄆ䛻ᚲせ䛺Ᏻᛶ䛺䜙䜃䛻᭷ຠᛶ䛾 䝕䞊䝍䜢ᚓ䜛䛯䜑䛾⮫ᗋヨ㦂䛷䛒䜛䚹䛣䜜䜙ᚋᮇ䛾㛤Ⓨ䛻䛿◊✲㛤Ⓨண⟬䛾ᐇ䛻㻤㻜䡚㻥㻜䠂䛜㈝䜔䛥䜜䜛 䛜䚸ᚲ䛪䛧䜒⛉Ꮫⓗ䛺䛔䛧ᢏ⾡ⓗ䛻᪂䛧䛔౯್䛜ຍ䛥䜜䜛䜟䛡䛷䛿䛺䛔䚹䛣䜜䜢䜶䜰䝞䝇㻟㻤㻜䛻䛘䜛䛺 䜙䜀䚸㛤Ⓨண⟬䛾㻤㻜䡚㻥㻜䠂䛜䚸⯟✵ᶵタィ䚸䛴䜎䜚෬㔠Ꮫ䚸䜶䝺䜽䝖䝻䝙䜽䝇䚸⯟✵ᕤᏛ䛺䛹䛾ྥୖ䛻㈝䜔䛥 䜜䜛䛾䛷䛿䛺䛟䚸ヨ㦂㣕⾜䛻㈝䜔䛥䜜䜛䜘䛖䛺䜒䛾䛷䛒䜛䚹ᛂ⏝⛉Ꮫ䛸䛧䛶䛾⣧⢋䛺◊✲άື䛣䛭䛜་⸆ရ ⏘ᴗ䛾ᑗ᮶䜢Ỵᐃ䛩䜛䜒䛾䛷䛒䜛䛜䚸䛭䛖䛧䛯◊✲άື䛻䛿་⸆ရ䛾◊✲㛤Ⓨ㈝⏝䛾䛤䛟୍㒊䛜ᡠ䛥䜜䜛 䛻㐣䛞䛺䛔䚹 ◊✲㛤Ⓨ㈝⏝䛾ᨭฟ䛜㛤Ⓨᮇ㛫䛾ᚋᮇ䛻೫䛳䛶䛔䜛䛯䜑䚸⸆䛜ኻᩋ䛧䜘䛖䜒䛾䛺䜙䚸䛭䛾ኻᩋ䛛䜙ᅇ 䛷䛝䜛䜒䛾䛿䜋䛸䜣䛹䛺䛔䚹䝃䝸䝗䝬䜲䝗䛾䜘䛖䛺እ䛿⛥䛻䛿䛒䜛䛜䚸་⸆ရ䛭䛾䜒䛾䛜ά䛩䜛䛣䛸䛿䛺䛔䚹 Figure 4: R&D Percent of Sales All industry composite 3.8 0.7 Metals & mining 0.8 Paper & forest products 3.9 Aerospace & defence 4.2 Automotive Electrical and electronics 4.9 Telecommunications 5.0 Leisure time products 5.3 8.1 Office equipment & services 11.2 Drugs and medicine Research-based pharmaceutical company 19.4 0 6 12 18 24 ‘Research-based pharmaceutical companies’ based on ethical pharmaceutical sales and ethical pharmaceutical R&D only, as tabulated by PhRMA. ‘Drugs and medicine’ category based on total R&D and sales for all products of companies within the drugs and medicine sector, tabulated by Standard & Poor’s Compustat, a McGraw-Hill Division. 4 Herper M. The Truly Staggering Cost of Inventing New Drugs. Forbes. 22 February 2012. Available from: http://www. forbes.com/sites/matthewherper/2012/02/22/the-truly-staggering-cost-ofinventing-new-drugs-the-print-version/ www.quintiles.com 4 ୍᪉䚸䝪䞊䜲䞁䜾㻣㻤㻣䛷䛿䚸䝔䝇䝖㣕⾜୰䛻Ⅳ⣲⧄⥔䛾⬗య䛻䜽䝷䝑䜽䛜⏕䛨䛯ሙྜ䛷䜒䚸タィ䜢ኚ᭦䛧䛶䝔䝇 䝖䛿㛤䛥䜜䛯䚹ྠᵝ䛻䚸䜶䜰䝞䝇㻟㻤㻜䛾䜶䞁䝆䞁䛜⇿Ⓨ䛧䛶䜒䚸䜶䞁䝆䞁䛾タィ䛸ᢏ⾡ⓗ䛺ᨵၿ䛻䜘䜛ᑐ ᛂ䛜䛸䜙䜜䚸䜶䜰䝞䝇㻟㻤㻜䛜ᕷሙ䛛䜙᧔㏥䛩䜛䛣䛸䛿䛺䛛䛳䛯䚹 䛥䜙䛻䚸་⸆ရ䛿䚸⸆䛛䜙ୖᕷ䜎䛷䛻୍ศ䛾୍䛸䜒ゝ䜟䜜䜛⊃䛝㛛䜢↓䛟䛠䜚ᢤ䛡䚸ୖᕷ䛻⮳䛳䛯䛸䛧䛶 䜒䚸䛭䛾〇ရᑑ䛿䚸≉チ䛜ᾘ⁛䛩䜛䜎䛷㻣䡚㻝㻜ᖺ䛸┦ᑐⓗ䛻▷䛔䚹䝪䞊䜲䞁䜾㻣㻟㻣䛿䚸Ⓩሙ䛧䛶⣙㻟㻡ᖺ䜢⤒ 䛶䛯⌧ᅾ䜒✵䜢㣕䜣䛷䛔䜛䚹䝷䜲䞁䜶䜽䝇䝔䞁䝅䝵䞁䛿ఱᗘ䛛ᐇ䛧䛯䛜䚸ᕷሙ䝅䜵䜰䛻䛚䛔䛶➇ྜ䛩䜛䛾 䛿䜶䜰䝞䝇䛰䛡䛷䛒䜛䚹䛣䜜䛻ᑐ䛧⡿ᅜ䛻䛚䛡䜛་⸆ရ䛿䚸୍⯡ⓗ䛻≉チᾘ⁛䛛䜙㻢䞃᭶௨ෆ䛻䚸ᚋⓎရ䛸䛾 ➇ྜ䛻䜘䜚ୖ䛾㻤㻜䡚㻥㻜䠂䜢ኻ䛳䛶䛧䜎䛖䚹 㛤Ⓨᮇ㛫䛾㛗ᮇ䛻䜘䜚䚸᪂⸆䜢ᕷሙ䛻ᥦ౪䛩䜛㈝⏝䛿㠀ᖖ䛻㧗㢠䛸䛺䜛䚹㈝⏝䛻䛴䛔䛶䛿ᵝ䚻䛺᥎ᐃ䛜 䛒䜚䚸㻡൨⡿䝗䝹䡚㻝㻜൨⡿䝗䝹㉸䛷䛒䜛䚹䛧䛛䛧䚸䜘䜚ṇ☜䛻᥎ᐃ䛩䜛䛺䜙䜀䚸〇⸆ᴗ䛾◊✲㛤Ⓨ㈝⏝䛾ྜ ィ㢠䜢ୖᕷ䛥䜜䛯〇ရ䛾ᡂຌᩘ䛷㝖䛧䛯㔠㢠䛸䛔䛖䛣䛸䛻䛺䜝䛖䚹䛣䛾ᑻᗘ䜢㻝㻥㻥㻣ᖺ䡚㻞㻜㻝㻝ᖺ䛾ᮇ㛫䛻⏝ 䛔䜛䛸䚸〇⸆ᴗୖ㻝㻞♫䛜ᕷሙ䛻ᢞධ䛧䛯ྛ᪂⸆䛾◊✲㛤Ⓨ㈝⏝䛿⭾䛺䜒䛾䛸䛺䜚䚸㛤Ⓨ䛥䜜䛯ศᏊ ᙜ䛯䜚䛷䚸ప㢠䛺䜒䛾䛿㻟㻣൨⡿䝗䝹䛛䜙㧗㢠䛺䜒䛾䛷䛿㻝㻝㻤൨⡿䝗䝹䛸䛺䛳䛯䚹㻠䚷 ᭱ᚋ䛻䚸䝬䞊䜿䝔䜱䞁䜾䛻㛵䛧䛶䜒ᴟ䜑䛶᫂░䛺㒊ศ䛜䛒䜛䚹᪂⸆䛜ୖᕷ䛥䜜䜛䛸䛝䚸䛭䛾㢳ᐈ䛿ㄡ䛺䛾䛛䚹 ከᩘ䛾་⸆ရ䛾୰䛛䜙ฎ᪉䛩䜛⸆䜢Ỵᐃ䛩䜛་⪅䛷䛒䜛䛾䛛䚹䛒䜛䛔䛿་⸆ရ䛾㈝⏝䜢ᨭᡶ䛖ಖ㝤 ♫䜔බඹ䛾䝥䝻䝞䜲䝎䞊䛷䛒䜛䛾䛛䚹䛭䜜䛸䜒ᝈ⪅䛷䛒䜛䛾䛛䚹ᝈ⪅䛾䛯䜑䛻་⸆ရ䛿㛤Ⓨ䛥䜜䛶䛔䜛䛸ゝ 䜟䜜䛶䛔䜛䛜䚸ᝈ⪅䛿〇ရ䛾ཷືⓗ䛺ཷྲྀே䛷䛒䜛䚹䛣䜜䜙䛾䝆䝺䞁䝬䜢䛹䛾䜘䛖䛻䛸䜙䛘䜛䛛䛿䛸䜒䛛䛟䚸་ ⸆ရ䜢ᡂຌ䛻ၟရ䛥䛫䜘䛖䛸䛩䜛䝥䝺䝑䝅䝱䞊䛿ᐇᏑⓗ䛻ᙉຊ䛺䜒䛾䛜䛒䜚䚸⤖ᯝⓗ䛻䚸✚ᴟⓗ㐣䛞䜛 䝬䞊䜿䝔䜱䞁䜾άື䛜〇⸆ᴗ⏺䛾ホุ䜢ᦆ䛽䛯䜚䚸つไᙜᒁ䛛䜙⭾䛺⨩㔠䜢⛉䛫䜙䜜䛯䜚䛩䜛䛣䛸䜒ከ䛔䚹 ゝ䛳䛶䛧䜎䛘䜀䚸་⸆ရ⏘ᴗ䛿ᅔ㞴䛺ᮇ䛻ᕪ䛧䛛䛳䛶䛚䜚䚸⬤ᙅ䛺ᇶ┙䛾ୖ䛻ᡂ䜚❧䛳䛶䛔䜛䛣䛸䛿䜒 䛿䜔ㄡ䜒↓ど䛷䛝䛺䛔䛸䛔䛖䛣䛸䛷䛒䜛䚹 ࢪࡢྎ㢌㸫ࡧ ඖ⡿ᅜ㈈ົ┬㛗ᐁ䛾䝷䝸䞊䞉䝃䝬䞊䝈䛿䚸䛂䜰䝆䜰⤒῭䛾ⓗ䛺㏆௦䛿䚸⤒῭ྐ䛻䛚䛡䜛᭱䜒㔜せ䛺Ⓨᒎ 䛾୍䛴䛸䛧䛶䚸䝹䝛䝑䝃䞁䝇䜔⏘ᴗ㠉䛻ẚ⫪䛩䜛䜒䛾䛷䛒䜛䛃䛸㏙䜉䛶䛔䜛䚹☜䛛䛻䚸䛯䛳䛯୍ୡ௦䛷㉳䛣䛳 䛯䜰䝆䜰䛾⯆㝯䛻䛿┠䜢ぢᙇ䜛䜒䛾䛜䛒䜛䚹⏘ᴗ㠉䛿䚸䜰䝆䜰䛻䛚䛡䜛୍ୡ௦䛾㛫䛻⏕άỈ‽䜢㻞ಸ䛻䛧 䛯䛜䚸䜰䝆䜰䛾༢୍ୡ௦䛾⯆㝯䛻䛚䛔䛶䛿୍ேᙜ䛯䜚䛾㻳㻰㻼䛜㻝㻜䡚㻝㻜㻜ಸ䜒ୖ᪼䛧䛯䚹㐣ཤ㻟㻜ᖺ㛫䛷䚸㈋ᅔ 䝷䜲䞁䜢ୗᅇ䜛⏕ά䜢䛧䛶䛔䜛ே䛾ྜ䜒䚸㻝㻥㻤㻝ᖺ䛾㻣㻤䠂䛛䜙㻞㻜㻜㻡ᖺ䛾㻝㻣䠂䛻పୗ䛧䛯㻡 䚹 ⡿ᅜ䛾␒ᗏ䛸䛺䜛ᬒẼᚋ㏥䜔Ḣᕞ䛾㏻㈌༴ᶵ䛺䛹䚸䜾䝻䞊䝞䝹䛺⤒῭༴ᶵ䛻䜒㛵䜟䜙䛪䚸䜰䝆䜰⤒῭䛿 Ᏻᐃⓗ䛻ᡂ㛗䜢⥅⥆䛧䛶䛔䜛䚹䜲䞁䝗䜔୰ᅜ䛺䛹䛾㻳㻰㻼ᡂ㛗⋡䛿㻢䡚㻤䠂⛬ᗘ䛻ῶ㏿䛧䛯䛛䜒䛧䜜䛺䛔䛜䚸 䛭䜜䛷䜒⡿ᅜ䜔㻱㼁䛾ண ᡂ㛗⋡䜘䜚䛿ఱಸ䜒㧗䛟䚸ᆅ⌫ୖ䛾㝣ሢ䛾㻟㻜䠂䜢༨䜑䚸ே㢮䛾㻢㻜䠂䛜ᬽ䜙䛩 㝣䛻䚸ኚ㠉䜢䜒䛯䜙䛧䛶䛔䜛䚹୰ᅜ䜔䜲䞁䝗䛻㛵䛩䜛䝙䝳䞊䝇䛜䝦䝑䝗䝷䜲䞁䜢⊂༨䛧䛶䛔䜛䛜䚸䛾䜰䝆䜰ㅖ ࢪࡣᐇ⌧௦ࡋ࡚ࡁ࡚࠸ࡿࡀࠊすὒࡋ࡚࠸ࡿ⪃࠼ࡿࡢࡣ㛫㐪࠸࡛ ࠶ࡿࠋ ࠕୡ⏺ⓗど㔝࡛⪃࠼ࠊ⌧ᆅ࡛ࣞ࣋ࣝ⾜ືࡍࡿࠖࡔࡅ࡛ࡣࠊ ࡶࡣࡸ༑ศ ࡛࠶ࡾࠕୡ⏺ⓗど㔝࡛⪃࠼ࠊ⌧ᆅࡢே㛫࡞ࡿࠖᚲせࡀ࠶ࡿࠋࡑࡢࡓࡵࡣࠊ ࠕ⌧ᆅࠖࡣఱࡓࡿࢆ┿⌮ゎࡋ࡞ࡅࢀࡤ࡞ࡽ࡞࠸ࠋ 5 The World Bank (Internet Page). Poverty & Equity: East Asia & Pacific. Available from: http://povertydata.worldbank.org/ poverty/region/EAP 5 www.quintiles.com Figure 5: The World’s 10 Largest Economies (GDP in US $ Billions) 80,000 2050 2040 2030 2020 2010 70,000 60,000 50,000 40,000 30,000 20,000 10,000 0 China United India Brazil States Goldman Sachs – BRICS and Beyond, 2007 Mexico Russia Indonesia Japan United Germany Kingdom ᅜ䜒ᛴ㏿䛻ᡂ㛗䛧䛶䛔䜛䚹䜲䞁䝗䝛䝅䜰䛿䚸୰ᅜ䚸䜲䞁䝗䚸⡿ᅜ䛻ḟ䛔䛷ୡ⏺㻠䛾ேཱྀ䜢᧦䛧䚸㻞㻜㻡㻜ᖺ䜎䛷䛻䛿䚸 ⱥᅜ䚸䝗䜲䝒䚸᪥ᮏ䜢䛔䛷䚸ୡ⏺㻣䛾⤒῭つᶍ䛻䛺䜛䛸ண 䛥䜜䛶䛔䜛㻌䠄ᅗ㻡䠅㻌䠄ᩘ್䛿ୡ⏺㖟⾜䠋䝂䞊䝹䝗 䝬䞁䝃䝑䜽䝇䠅䚹䝧䝖䝘䝮䛿䚸䝗䜲䝒䛻༉ᩛ䛩䜛ேཱྀ㻤㻡㻜㻜䜒䛾ேཱྀ䜢ᢪ䛘䛶䛚䜚䚸ᡂ㛗⋡䛿୰ᅜ䛸ྠ⛬ᗘ䛷䛒䜛䚹 䜰䝆䜰䛿☜䛛䛻㏆௦䛧䛶䛔䜛䛜䚸䜰䝆䜰㝣䛜すὒ䛧䛶䛔䜛䛸⪃䛘䜛䛾䛿㛫㐪䛔䛷䛒䜛䚹䜰䝆䜰ே䛿䚸す ὒ䛧䛯㣗≀䚸ᩥ䛚䜘䜃⏕άᵝᘧ䜢ぬ䛘䛯䛜䚸ᆅᇦᩥ䜔䜰䜲䝕䞁䝔䜱䝔䜱䛜䜃ᙇ䛥䜜䛶䛔䜛䛾䜒☜䛛 䛷䛒䜛䚹䛣䜜䛿䚸䜾䝹䞊䝞䝹䛺ከᅜ⡠ᴗ䛜⌮ゎ䛩䜛ᚲせ䛾䛒䜛ᇶᮏⓗ䛺䝫䜲䞁䝖䛷䛒䜛䚹ᴗ䛿䛂䜾䝻䞊䝞䝹 䛻⪃䛘䚸ᆅᇦ䛷⾜ື䛩䜛䛃䛰䛡䛷䛿䚸䜒䛿䜔༑ศ䛸䛿ゝ䛘䛺䛔䚹䜐䛧䜝ᴗ䛿䛂䜾䝻䞊䝞䝹䛻⪃䛘䚸ᆅᇦ䛻᰿ᕪ 䛩䛃ᚲせ䛜䛒䜚䚸䛂ᆅᇦ䛻᰿ᕪ䛩䛃䛯䜑䛻䛿䚸ᴗ䛿䛂ᆅᇦ䛃䛜┿䛻ព䛩䜛䛸䛣䜝䜢⌮ゎ䛧䛺䛡䜜䜀䛺䜙䛺䛔䚹 䛘䜀䚸ᝈ⪅䛜䜾䝻䞊䝞䝹〇⸆ᴗ䛾ᐇ䛩䜛⮫ᗋヨ㦂䛻ཧຍ䛩䜛䛻䛒䛯䜚䚸䛭䜜䛻ᑐ䛩䜛䜲䞁䝗ᨻᗓ䛾 ぢゎ䜢⌮ゎ䛩䜛䛯䜑䛻䛿䚸ᾏእᴗ䜔ᾏእᨻᗓ䛜䚸Ṕྐⓗ䛻ྠᅜ䛷ᯝ䛯䛧䛶䛝䛯ᙺ䜢ṇ䛧䛟ㄆ㆑䛩䜛ᚲ せ䛜䛒䜛䚹䜾䝻䞊䝞䝹⤒῭䛻䛚䛡䜛୰ᅜ䜔䜲䞁䝗䛾ྎ㢌䛿㏆ᖺ䛾䜒䛾䛸⪃䛘䛶䛔䜛ே䛜ከ䛔䛜䚸୧ᅜ䛾Ṕྐ 䜢㻡㻜㻜㻜ᖺ㐳䜛䛸䚸ୡ⏺⤒῭䛻ᙳ㡪䜢䛘䛯䛾䛿ᅇ䛜ึ䜑䛶䛷䛿䛺䛔䛣䛸䛜ゎ䜛䚹 㐣ཤ䛾㻞㻜㻜㻜ᖺ㛫䛻䛚䛔䛶䚸᭱ึ䛾㻝㻤㻜㻜ᖺ㛫䛿䚸䜰䝆䜰䛜ୡ⏺⤒῭䜢ᨭ㓄䛧䛶䛚䜚䚸䜲䞁䝗䛸୰ᅜ䜢ྜ䜟䛫䜛 䛸䚸ୡ⏺䛻䛚䛡䜛⏕⏘≀䛾ྜィ䛾㻡㻜䠂௨ୖ䜢༨䜑䛶䛔䛯㻢䠄ᅗ㻢䠅䚹㻝㻤ୡ⣖ᚋ༙䚸⏘ᴗ㠉䜢క䛳䛯すὒ䛻䜘 䜛䜰䝆䜰䛾᳜Ẹᆅ䛿䚸Ḣᕞ䛻㇏䛛䛥䜢䚸䜰䝆䜰䛻䛿㈋ᅔ䜢䜒䛯䜙䛧䛯䚹䛣䛾ฟ᮶䛜䛹䛾䜘䛖䛻䛧䛶㉳䛣䛳䛯 䛛䜢⌮ゎ䛩䜛䛣䛸䛷䚸䜰䝆䜰䛜すὒ䜢䛹䛾䜘䛖䛻ぢ䛶䛔䜛䛛䛻䛴䛔䛶Ὕᐹ䜢῝䜑䜛䛣䛸䛜䛷䛝䜘䛖䚹 㻝㻣㻡㻣ᖺ䛻䜲䞁䝗䛾୍㒊ᆅᇦ䛻䛚䛔䛶᭱ึ䛾㡿ᅵᨭ㓄䜢⾜䛳䛯䛾䛿ⱥᖇᅜ䛷䛿䛺䛟䚸ᮾ䜲䞁䝗♫䛷䛒䛳 䛯䚹ᮾ䜲䞁䝗♫䛸䛿䚸䛣䛾㻝ୡ⣖䜒๓䛻䚸㈠᫆䛸䛔䛖ྡ┠䛷䜲䞁䝗䛻㐍ฟ䛧䛯ᰴᘧ♫䛷䛒䛳䛯䚹ᮾ䜲䞁䝗 ♫䛜䝧䞁䜺䝹䜢ᨭ㓄䛩䜛䜘䛖䛻䛺䛳䛶䛛䜙㻝㻜ᖺ䜒⤒䛯䛺䛔䛖䛱䛻䚸㻟ᖺ㛫䛻䜒ཬ䜆ᝒ䛺㣚㣹䛜Ⓨ⏕䛧 䛯䚹㻝㻜㻜㻜ே䛜Ṛஸ䛧䚸䝧䞁䜺䝹䛾ேཱྀ䛿୕ศ䛾୍䜒ῶᑡ䛧䛯䚹㣚㣹䛾ཎᅉ䛿䚸⛯㔠䛜㻝㻜䠂䛛䜙㻡㻜䠂䛻ᘬ䛝 ୖ䛢䜙䜜䛯䛣䛸䠄ᅜእ䛻ὶฟ䛩䜛ṓධ䠅䚸✐≀䛾స䚸䛺䜙䜃䛻㎰స≀䛾ᙉไⓗᨺᲠ䠄୰ᅜ䛸䛾ึᮇ䜰䝦䞁㈠ ᫆䛾䛯䜑䛻䜿䝅䛾᱂ᇵ䜢ඃඛ䛩䜛䛯䜑䠅䛷䛒䛳䛯䚹 6 Maddison A. Contours of the World Economy 1-2030 AD: Essays in Macro-Economic History. Oxford University Press, USA. 2007 www.quintiles.com 6 Figure 6: Percentage of Total World GDP – a two thousand year view 100% Rest of World 90% Western offshoots West Europe 80% Japan 70% India China 60% 50% 40% 30% 20% 10% 0% 1 1000 1500 1600 1700 1820 1870 1913 1950 1973 2003 Data extracted from: Contours of the World Economy, Angus Maddison (2007) 䛣䛾Ṕྐୖ䛾୍᩿∦䜢⌮ゎ䛩䜛䛰䛡䛷䜒䚸䜲䞁䝗ேάືᐙ䛜ྠᅜ䛷⮫ᗋヨ㦂䜢ᐇ䛩䜛ከᅜ⡠〇⸆ᴗ䛻 ᑐ䛧ᠱᛕ䜢ᢪ䛔䛶䛔䜛䛣䛸䜔⡿ᅜ䛸䜲䞁䝗䛾᰾ྜព䛻ᑐ䛧䛶䛔䜛⌧ᅾ䛾≧ἣ䜢䚸䜘䜚ṇ䛧䛟⌮ゎ䛧䚸䜘䜚῝䛔 㓄៖䜢ᣢ䛳䛶䜏䜛䛣䛸䛜䛷䛝䜛䚹ከᅜ⡠་⸆ရᴗ䛜ά䜢ᯝ䛯䛩ୖ䛷䜰䝆䜰䛜㔜せ䛸䛺䜛䛣䛸䛻䛔䛾వ ᆅ䛿䛺䛟䚸᪂⯆ᕷሙᡓ␎䛜ᡂຌ䛩䜛䛯䜑䛻䛿䚸ḟ䛾୕䛴䛾ᇶᮏⓗ┿⌮䛻ᇶ䛵䛔䛶㐍䜑䛶䛔䛟ᚲせ䛜䛒䜛䚹 ➨୍䛻䚸䜰䝣䝸䜹䛜༢୍ᅜ䛷䛺䛔䛾䛸ྠ䛨䜘䛖䛻䚸䜰䝆䜰䛿༢୍య䛷䛿䛺䛔䚹䜰䝆䜰䛿䚸᭱䜒䛝䛺㝣ሢ䛻䛒䜛 ᭱䜒ேཱྀ䛾ከ䛔㝣䛷䛒䜛䛜䚸ྠ䛻ከᵝᛶ䛻䜒ᐩ䜣䛷䛔䜛䚹⡿ᕞ䜔Ḣᕞ䛜㝣䛸䛧䛶ẚ㍑ⓗᆒ୍䛷䛒䜛 䛾䛻ᑐ䛧䛶䚸䜰䝆䜰䛿䚸ゝㄒ䚸ᩥ䚸᐀ᩍ䚸Ẹ᪘䚸ᨻ䛾Ⅼ䛷ᴟ䜑䛶ᆒ୍䛷䛒䜛䚹䜎䛯䚸䜰䝆䜰䛿䜲䞁䝗䛸୰ᅜ 䜢༢䛻㊊䛧ྜ䜟䛫䛯䜒䛾䛷䛿䛺䛔䚹ከ䛟䛾䜰䝆䜰⤒῭䛜ᛴ㏿䛻⯆䜢䜏䛫䛶䛚䜚䚸䛣䜜䜙䛾⤒῭䛿㔜せ䛺ᡂ 㛗ᶵ䜢ᥦ౪䛧䛶䛔䜛䛸䛔䛖ほⅬ䛛䜙䜒ㄆ㆑䛥䜜䜛䜉䛝Ꮡᅾ䛷䛒䜛䚹䛣䜜䛿䚸↓୍ᩥ䛛䜙㔠ᣢ䛱䛻䛺䛳䛯 ヰ䠄䜰䝯䝸䜹䞁䝗䝸䞊䝮䛸㔜䛽ྜ䜟䛫䜙䜜䜛㢮䛾≀ㄒ䠅䛺䛹䛷䛿䛺䛟䚸䜰䝆䜰ά䛾ヰ䛷䛒䜛䚹䛣䛾㐪䛔䛿䚸䝻䝬 䞁䝔䜱䝑䜽䛺⪃䛘䛻䜘䜛䜒䛾䛷䛿䛺䛟䚸ᴟ䜑䛶㔜せ䛺㐪䛔䛷䛒䜚䚸䛣䛾㐪䛔䛣䛭䛜䚸〇⸆ᴗ䜢ᑟ䛝䚸䜰䝆䜰䛷 䛾ᴗ☜❧䛻ᚲせ䛺୰㛗ᮇⓗどⅬ䜢䜒䛯䜙䛩䚹᪂⯆ㅖᅜ䛻᰿ᕪ䛧㛵ಀᵓ⠏䜢ᮃ䜐ᴗ䛻䛸䛳䛶䚸᭱䜒㈼᫂ 䛺ཧධ䝍䜲䝭䞁䜾䛿䚸᪂⯆ㅖᅜ䛜⯆㝯䛾๓ẁ㝵䛷䛒䜚䚸᪂⯆䛩䜛䜲䞁䝣䝷䛻ᑐ䛩䜛㔜せ䛺ᢞ㈨䛻䛚䛔䛶䚸す ὒ䛾ᴗ䛻ᨭ䜢ồ䜑䛶䛔䜛ᮇ䛷䛒䜛䚹 ➨䛻䚸䛂ᅜ䛃䜢䛂ᕷሙ䛃䛸ྠ䛨ព䛸䛧䛶⪃䛘䜛ഴྥ䛜䛒䜛䚹䛴䜎䜚䚸䛂᪂⯆ᕷሙ䛃䛸䛔䛖⏝ㄒ䛿䚸ᛴ㏿䛻ᡂ㛗䛧䛶 䛔䜛ᅜ䜔♫య䜢♧䛩⊃䛔ᥦ႘䛸䛧䛶⏝䛔䜙䜜䛶䛔䜛䚹䛣䛾䛯䜑䚸䛥䜙䛻῝้䛺㛫㐪䛔䛸䛧䛶䚸Ṕྐⓗ䛚䜘 䜃ᩥⓗ䛺㐪䛔䜢⪃៖䛫䛪䛻䚸䜰䝆䜰䜢すὒᕷሙ䛾༢䛺䜛ᘏ㛗䜎䛯䛿ᣑ䛸䛧䛶⾲㠃ⓗ䛻ぢ䛶䛧䜎䛖䛣䛸䛻 䛺䜛䚹Ⓨᒎ䛸㏆௦䛻క䛔䚸䜰䝆䜰䛾ྛᅜ䛿⮬ᅜ䛾≉ᚩⓗ䛛䛴ᩥⓗ䛺䜰䜲䝕䞁䝔䜱䝔䜱䜢䜘䜚㩭᫂䛻♧䛩 䛿䛪䛷䛒䜛䚹䛔䛛䛺䜛⏘ᴗ䛻䛚䛔䛶䜒䚸䜰䝆䜰䛷ᡂຌ䛧䛯䛔䛸⪃䛘䛶䛔䜛ከᅜ⡠ᴗ䛿䚸䛂ᆅᇦ䛻᰿ᕪ䛩䛃䛣 䛸䜢Ꮫ䜃䚸౯್䜢㐀䛩䜛ᙜᆅ䛾ᴗᶵ䜢ㄆ㆑䛧䚸䛣䜜䜢ά⏝䛧䛶䛔䛟ᚲせ䛜䛒䜛䚹 ᭱ᚋ䛻䚸䜰䝆䜰ᡂ㛗䛾ึᮇẁ㝵䛿䚸ᢏ⾡ຊ䛾䛺䛔〇ရ䛸ປാຊ䛻䜘䜛䝁䝇䝖㠃䛷䛾㠧✌䛞䠄㼏㼛㼟㼠㻙㼍㼞㼎㼕㼠㼞㼍㼓㼑䠅 7 www.quintiles.com 䛻䜘䛳䛶ᨭ䛘䜙䜜䛶䛝䛯䛜䚸⌧ᅾ䛿䚸▱ⓗ㈨ᮏ䛜୰ᅜ䜔䜲䞁䝗䜈㏫ὶ䛧䛶䛚䜚䚸㻹㻵㼀䜔䝇䝍䞁䝣䜷䞊䝗䛷⩦ᚓ䛥 䜜䛯⛉Ꮫ䜔ᢏ⾡䝇䜻䝹䛜䚸Ṋ₎䜔䝞䞁䜺䝻䞊䝹䛻䛧䛳䛛䜚䛸᰿䜢ୗ䜝䛧䛶䛝䛶䛔䜛䚹㧗ရ㉁䛾་⸆〇ရ䛻䛚 䛔䛶䚸୰ᅜ䜔䜲䞁䝗䛜➇ྜ䛩䜛䛣䛸䛿䛺䛔䛸⪃䛘䛶䛔䜛ே䛿䚸㻝㻥㻥㻜ᖺ௦䛻㡑ᅜ〇⮬ື㌴䛜䛒䛦➗䜟䜜䛶䛔䛯 䛣䛸䚸䛭䜜௨๓䛷䛿᪥ᮏ䛾䜶䝺䜽䝖䝻䝙䜽䝇䛜➗䛔䜒䛾䛸䛥䜜䛶䛔䛯䛣䛸䛻┠䜢ྥ䛡䜛䜉䛝䛷䛒䜛䚹䜰䝆䜰䛾⯆㝯 䛸䛿䚸ᕷሙ䛸䛧䛶䛰䛡䛷䛿䛺䛟䚸⤒῭ⓗ䛻Ⓨᒎ䛧ᢏ⾡ⓗ䛻䜒㐍Ṍ䛧䛯ᅜ䛾ከᵝ䛺㞟ᅋ䛸䛧䛶䛾⯆㝯䛷䛒䜚䚸䛭 䜜䛮䜜䛾ᅜ䛿ከᴟ䛾ୡ⏺䛻⮬ᅜ䛾ᆅ䜢⠏䛣䛖䛸䛧䛶䛔䜛䚹 ⌧ᐇ䛸䛿䚸ே䛾▱ᛶ䛜䛭䛾䛶䜢⌮ゎ䛷䛝䜛䜋䛹ᑠ䛥䛔䜒䛾䛷䛿䛺䛔䚹Ṕྐ䛿Ꮫᰯ䛷ᩍ䜟䜛䝅䞁䝥䝹䛺ヰ 䜘䜚䜒䛿䜛䛛䛻」㞧䛷䛒䜛䚹ே䜢ຓ䛡ⱞ䛧䜏䛾⦆䜢᥈✲䛩䜛⏘ᴗ䛻䛚䛔䛶䛿䚸⑂ᘢ䛧䛶ᔂቯ䛧䛭䛖䛺䝰䝕 䝹䛷䛒䛳䛶䜒䚸ᆅᇦ䜢⌮ゎ䛧䚸ᆅᇦ䛻᰿ᕪ䛧䚸ᆅᇦ䛷⪃䛘䜛䛣䛸䛻䜘䛳䛶䚸䜰䝆䜰䛷䛾䜲䞁䝇䝢䝺䞊䝅䝵䞁䜢᥈ ✲䛷䛝䜛䛷䛒䜝䛖䚹ᖺ⪁䛔䛯║䛷䚸䜰䝆䜰䜢すὒ䛾ᘏ㛗䛸䛧䛶ぢ䛶䛔䛶䛿䚸䛭䜜䛿ྍ⬟䛷䛒䜛䚹 ᚋྥࡅ࡚㐍ⓗ࡞㠉᪂࡛ࡣ࡞ࡃࠊኚ㠉 㠉᪂䜔ኚ䛿䛴䛾ẁ㝵䛷⏕䛨䜛䚹୍ḟኚ䛸䛿䚸ᇶᮏⓗ䛺≧ែ䛿ኚ᭦䛫䛪䛻䚸ᆒ⾮䜢ᅇ䛩䜛䝋䝸䝳䞊 䝅䝵䞁䛸䛔䛘䜛䚹䛣䛾ሙྜ䚸ၥ㢟䜢⏕䜏ฟ䛧䛯యไ䜔ᵓ㐀䛿ኚ䜟䜙䛺䛔䜎䜎䛷䛒䜛䚹୍᪉䚸ḟኚ䛿䚸≧ែ 䛭䛾䜒䛾䛾ኚ䛷䛒䜚䚸ᯟ⤌䜏య䛾ኚ᭦䜎䛯䛿ኚ㠉䛷䛒䜛䚹䛸䛧䛶䚸≀䛻㏣䛔䛛䛡䜙䜜䜛ክ䜢ぢ䛶䛔䜛 ே䜢ྲྀ䜚ୖ䛢䛶䜏䜘䛖䚹ክ䜢ぢ䛶䛔䜛ே䛿䚸㉮䛳䛯䜚䚸㞃䜜䛯䜚䚸䜚ྥ䛔䛶≀䛻❧䛱ྥ䛛䛳䛯䜚䛩䜛䛜䚸䛣䜜 䜙䛿䛔䛪䜜䜒୍ḟኚ䛷䛒䜚䚸ክ䜢ぢ⥆䛡䛶䛔䜛௨ୖ䛿≀䛜Ꮡᅾ䛧䛶䛔䜛䛸䛔䛖ᯟ⤌䜏䛻ኚ䛿䛺䛔䚹䛧 䛛䛧䚸ክ䛛䜙┠ぬ䜑䛯▐㛫䚸≀䛿Ꮡᅾ䛧䛺䛟䛺䜛䚹䛣䛾┠ぬ䜑䛜ḟኚ䛷䛒䜛䚹 ་⸆ရᴗ⏺䛾ᩆୡ䛿㠉᪂䛷䛒䜛䛸ゝ䜟䜜䛶䛚䜚䚸䛣䛖䛧䛯ពぢ䛿㢖⦾䛻⪺䛛䜜䜛䚹ᐇ䚸᪂䛧䛔་⸆ရ䛜 Ⓨぢ䛥䜜䚸䠄ᚎ䚻䛻ῶᑡ䛩䜛䛻䛧䛶䜒䠅㏻ᖖ䛾㢖ᗘ䛷㛤Ⓨ䛜㐍䜑䜙䜜䛯ሙྜ䚸㐣ཤᩘ㻝㻜ᖺ㛫䛻䛚䛔䛶ᴗ⏺䛻 䛿䜋䛸䜣䛹㠉᪂䛿Ꮡᅾ䛧䛺䛛䛳䛯䛸ㄽ䛨䜛䛣䛸䜒䛷䛝䜛䛰䜝䛖䚹䛥䜙䛻䚸๓㏙䛧䛯୍㐃䛾ㄢ㢟䛻㚷䜏䜛䛸䚸᪤Ꮡ 䛾䝞䜲䜸〇⸆䝰䝕䝹䛾ᇶᮏⓗ䛺ᵓ㐀ⓗḞ㝗䜢ඞ᭹䛩䜛䛾䛻㐍ⓗ㠉᪂䛷༑ศ䛛䛹䛖䛛䚸䛭䛧䛶᪂⸆䛾㛤 Ⓨ䛻ᑐ䛩䜛⪃䛘᪉䜔䜰䝥䝻䞊䝏䛻㻝㻤㻜ᗘ䛾ኚ㠉䛜ᚲせ䛹䛖䛛䚸ၥ䛜ṧ䜛䚹䜰䜲䞁䝅䝳䝍䜲䞁䛜㏙䜉䛶䛔䜛䜘 䛖䛻䚸䛂⌧ᅾᡃ䚻䛜┤㠃䛧䛶䛔䜛㔜䛺ၥ㢟䜢䚸䛭䛾ၥ㢟䛜⏕䛨䛯㡭䛾ᡃ䚻䛸ྠ䛨䝺䝧䝹䛾ᛮ⪃䛷ゎỴ䛩䜛 䛣䛸䛿䛷䛝䛺䛔䛃䛾䛷䛒䜛䚹 ་⸆ရ䛾ᴗ䝰䝕䝹䛿⌧ᅾ䚸ኚ㠉䛾ᒱ㊰䛻❧䛳䛶䛔䜛䚹ᪧ䝰䝕䝹䜢⌧ᅾ䛾ᙧ䛷ᣢ⥆䛩䜛䛣䛸䛿ྍ⬟䛷䛒 䜚䚸䜎䛯ᚋᣢ⥆䛥䜜䜛䛣䛸䜒䛺䛟䚸䛣䛾ᐇ䜢ㄆ㆑䛧⏝䛩䜛ே䚻䛣䛭䛜᪂䛧䛔䝰䝕䝹䜢ᙧస䜛䛾䛷䛒䜛䚹䛣䛾 ኚ㠉䛜䛹䛾䜘䛖䛺䜒䛾䛻䛺䜛䛛䛿䚸᥎ 䛾ᇦ䜢ฟ䛺䛔䚹་⸆ရᴗ⏺䛜ᡂຌ䜢䜑䜛䛯䜑䛻䛿䚸㔜䛺䜙䛺䛡䜜䜀 䛺䜙䛺䛔㍯䛜䛔䛟䛴䛛Ꮡᅾ䛩䜛䚹䛭䛾㍯䛸䛿䛴䜎䜚䚸㠉᪂䛿ᝈ䜔ⱞ䛧䜏䜢⦆䛩䜛䜒䛾䛷䛺䛡䜜䜀䛺䜙䛺䛔䚹 Ẽ䜔ⱞ䛧䜏䜢ᢪ䛘䜛ே䚻䛿䛣䜜䜙䛾㠉᪂䛻ᡭ䛜ᒆ䛟ᚲせ䛜䛒䜛䚹䛭䛧䛶䚸䛣䜜䜙䛾㠉᪂䛾⏝䛿䛥䜙䛺䜛㠉 ᪂䜢่⃭䛩䜛䛯䜑䚸㠉᪂⪅䛻䛿ぢ㏉䜚䛸䛧䛶ሗ㓘䜢䛘䜛ᚲせ䛜䛒䜛䚹䛣䜜䜙䛾㍯䛿ぢ㏉䜚䛸䛧䛶䚸䜘䜚䛝䛺 ♫య䛾㍯䚸䛴䜎䜚つไᙜᒁ䚸་⒪⌮䚸බ⾗⾨⏕䛜ྵ䜎䜜䛶䛚䜚䚸䜘䜚ᗈ⠊䛺┈䛸䛔䛖䛣䛸䛜ゝ䛘䜛䚹 䛧䛯䛜䛳䛶䚸᪂䛧䛔䝰䝕䝹䛻䛚䛔䛶㔜せ䛸䛺䜛䛾䛿䚸་⒪䛻ᑐ䛧᪂䛯䛺↔Ⅼ䜢ᙜ䛶䜛䛣䛸䛷䛒䜚䚸ಶே䛾ⱞ③ 䜢⦆䛧䚸♫䛜ᚲせ䛸䛧䛶䛔䜛་⒪䛻ྲྀ䜚⤌䜐䛣䛸䛷䛒䜛䚹䛤䛟ᑡᩘ䛾ᝈ⪅䛰䛡䛜⏝䛷䛝䜛㧗㢠䛾᪂⸆ 䜢㛤Ⓨ䛧䚸䛭䛾㈝⏝䛾䛯䜑䛻⤒Ⴀ㈨※䜢྾䛔ྲྀ䜙䜜䚸䛝䛺་⒪ㄢ㢟䜢䛺䛚䛦䜚䛻䛧䛶䛔䜛䜘䛖䛷䛿䜒䛿䜔 ༑ศ䛸䛿ゝ䛘䛺䛔䚹᪂䛯䛺䝰䝕䝹䛾᰾ᚰ䛻䛫䜎䜛䜘䛖䛺㉁ၥ䜢䛩䜛䛺䜙䜀䚸䛂ᝈ⪅䛾䛯䜑䛾㠉᪂ⓗ䛺䝋䝸䝳䞊 䝅䝵䞁䜢㐀䛧䚸䜘䜚ᗣⓗ䛺♫䜢ᐇ⌧䛩䜛䛯䜑䛻䚸⛉Ꮫ䜔ᢏ⾡䛿ఱ䛜䛷䛝䜛䛾䛛䛃䛸䛔䛖䛣䛸䛷䛒䜛䚹 䛣䛾᪂䛧䛔䝰䝕䝹䛻ᑐ䛩䜛ᇶᮏ䛿䝟䞊䝖䝘䞊䝅䝑䝥䛷䛒䜛䛸๓䛻㏙䜉䛯䚹㻣㻌୍ಶே䜔୍ᴗయ䛜䚸་⒪ య䛾ၥ㢟䜢ᢕᥱ䛩䜛䛣䛸䛿ᮃ䜐䜉䛟䜒䛺䛔䛧䚸䝋䝸䝳䞊䝅䝵䞁䛾䛶䜢ᡭ䛻䛩䜛䛣䛸䜒䜎䛯ྍ⬟䛷䛒䜛䚹་⸆ ရ㛤Ⓨ䛾ᪧ䝰䝕䝹䛷䛿䚸〇⸆ᴗ䛿⸆䛚䜘䜃⮫ᗋ㛤Ⓨ䝥䝻䝉䝇య䜢ಖ䛳䛶䛔䛯䚹䛣䛾┤⥺ⓗ䛷୍య ᆺ䛾䛂⊂ຊ䛃䝰䝕䝹䛿䚸ከᅜ⡠䛾䝟䞊䝖䝘䞊䝅䝑䝥䛚䜘䜃ᡓ␎ⓗ䜰䝷䜲䜰䞁䝇䛷䛒䜛䛂㌴㍯䛸䝇䝫䞊䜽䛃䛾䝰䝕 䝹䛻ྲྀ䛳䛶௦䜟䜙䜜䜘䛖䛸䛧䛶䛔䜛䚹᪂䛧䛔䝰䝕䝹䛷䛿䚸䛂ඹ䛻ᡂຌ䛩䜛䛯䜑䛻䛿ఱ䜢䛩䜉䛝䛛䛃䛸䛔䛖ཎ๎䛻 7 Kureishi A. Asia: A New Frontier for Strategic Drug Development. Quintiles. 8 March 2011. Available from: http://www.quintiles.com/information-library/white-papers/asia-new-frontier-strategic-drug-development/ www.quintiles.com 8 Figure 7: Shifting Paradigms in R&D: from Linear to Wheel and Spoke LINE AR MODEL > > > > > “Go at it alone” Large commitment of resources Diffuse focus Long PD cycle Competitive > > > > > Partnership & alliances Flexibility in allocating resources Focus on strengths Shorter “pay back” cycle Collaborative MA GL N IA AS zat S iali C’ e rc N mm AL M Co OB Re g u Stra lator y te g y AR BI PH l ic a e nt Clinlopm ve De O WHEEL & SPOKE MODEL o st ce s al Ac apit C ion Service Hub Companies c ov A ss er y et S e ar ch CO S H EC ufac Man R S og y SE CE co l HE VI i Tox NIC turin g D is BI O T ’S ⤖䜃䛴䛟䜒䛾䛷䛒䜚䚸䛂┦ᡭ䜘䜚ඛ䛻ᡂຌ䛩䜛䛯䜑䛻䛿ఱ䜢䛩䜉䛝䛛䛃䛸䛔䛖⪃䛘᪉䛷䛿䛺䛔䚹䛣䜜⮬య䛜䝟䝷 䝎䜲䝮䝅䝣䝖䛷䛒䜛䚹㻌䠄ᅗ㻣䠅 䛣䛾㌴㍯䛸䝇䝫䞊䜽䛾䝰䝕䝹䛻䛿䚸〇⸆ᴗ䛸䛭䛾ᚑ᮶䛾䝃䞊䝡䝇ᥦ౪⪅䚸䛩䛺䜟䛱㻯㻾㻻䛸䛾㛵ಀ䛾ኚ㠉 䛜క䛖䚹〇⸆ᴗ䛿䚸➇ྜ♫䛻䛴䛯䜑䛻⤒Ⴀ㈨※䜢㞟୰䛩䜛୍᪉䚸⸆䛸㛤Ⓨ䜢ᡂຌ䛥䛫䜛䛯䜑䛻䛿 ಙ㢗䛷䛝䜛䝟䞊䝖䝘䞊䛸䛾Ᏻᐃⓗ䛺ᥦᦠ㛵ಀ䜢ಖ䛴ᚲせ䛜䛒䜛䚹ᚑ᮶䛾㻯㻾㻻䛿䚸䜔䛭䛾⬟ຊ䜢ᣑ䛧䚸 䝃䞊䝡䝇ᥦ౪⪅䛛䜙㠉᪂ⓗ䝋䝸䝳䞊䝅䝵䞁䛾㐀⪅䜈䛸㐍䛧䛴䛴䛒䜚䚸་⸆ရ㛤Ⓨయ䜢ᶓ᩿ⓗ䛻ぢΏ 䛩䛣䛸䛾䛷䛝䜛≉ᛶ䜢ά⏝䛧䛶䛔䜛䚹䛣䛖䛧䛯㐍䛾䛸䛧䛶䚸䜽䜲䞁䝍䜲䝹䝈䛿䜰䝆䜰䛾ᡓ␎ⓗ་⸆ရ㛤Ⓨ䝴 䝙䝑䝖䜢䝅䞁䜺䝫䞊䝹䛻タ❧䛧䛶䛚䜚䚸䜰䝆䜰䛷་⸆ရ㛤Ⓨ䛾ᶵ䜢ᶍ⣴䛧䛶䛔䜛〇⸆ᴗ䛻⮫ᗋ㛤Ⓨ䛚 䜘䜃つไ㛵㐃䛾ᡓ␎䜢ᥦ౪䛧䛶䛔䜛㻌䠄ᅗ㻤䠅䚹㢳ᐈᴗ䛿䚸䝪䝖䝮䜰䝑䝥䛾་⒪䝁䞁䝔䜽䝇䝖䜢ᚓ䜛䛣䛸䛷⮬♫ 〇ရ䛸䜰䝆䜰䛾་⒪ⓗᒎᮃ䛜ྜ⮴䛩䜛ሙᡤ䜢ᶍ⣴䛩䜛䛣䛸䛜䛷䛝䚸䛥䜙䛻䚸ከᵝ䛺つไ䝅䝘䝸䜸䜢ぢᴟ䜑䛺 䛜䜙་⸆ရ䛾≉ᛶ䛻ྜ䜟䛫䛯⮫ᗋ㛤Ⓨᡓ␎䜢❧䛶䜛䛣䛸䛜䛷䛝䜛䚹 9 www.quintiles.com Figure 8: Strategic Drug Development Asia: Our Offerings Clinical Practices and Business Context Asian Regulatory Framework Clinical Development Plan for Asia 䜰䝆䜰䛷䛾ᡂ㛗䛿䚸་⸆ရ⏘ᴗ䛜⏕䛝ṧ䜛䛯䜑䛾୰᰾䛸䛺䛳䛶䛔䜛䚹ᐇ䚸⡿ᅜ䜔Ḣᕞ䛾〇⸆ᴗ䛾ከ䛟 䛿䚸᪂⯆ᕷሙᡓ␎䜢ᣢ䛳䛶䛚䜚䚸ᑗ᮶┈䛾㒊ศ䛜᪂⯆ᕷሙ䛛䜙ᚓ䜙䜜䜛䜒䛾䛸ᮇᚅ䛧䛶䛔䜛䚹䛻䜒䛛䛛 䜟䜙䛪䚸䜰䝆䜰䛻䛚䛡䜛ᡂ㛗ᶵ䛿䚸ᮍ䛰೫⊃䛺ぢ᪉䜢䛥䜜䛶䛔䜛䛾䜒ᐇ䛷䛒䜛䚹䛸䛔䛖䛾䜒䚸䜾䝻䞊䝞䝹䛺 〇⸆ᴗ䛿䚸᪂⯆ᅜ䜢すὒᕷሙ䛾ᘏ㛗䜔ᣑ䛸䛧䛶⪃䛘䛶䛚䜚䚸⊂≉䛷㦫␗ⓗ䛺ኚ㠉䛻䛺䜛䛸䛿⪃䛘䛶䛔 䛺䛔䚹་⸆ရ⏘ᴗ䛿䚸ୡ⏺䛾୰䛷䜒≉䛻䜰䝆䜰䛻䛚䛔䛶䛿䚸㐍ⓗ䛺㠉᪂䛷䛿䛺䛟䚸䝟䝷䝎䜲䝮䝅䝣䝖䚸䛴䜎䜚䛂 ⏕䜎䜜ኚ䜟䜛䛣䛸䛃䜢ᶍ⣴䛩䜛䜉䛝䛷䛒䜛䚹 䜰䝆䜰䛻䛿䚸་⸆ရ⏘ᴗ䛜ồ䜑䛶䛔䜛䛒䜙䜖䜛ኚ㠉䛾✀䛜Ꮡᅾ䛩䜛䚹䜰䝆䜰䛻䛿䚸つᶍ䛺⤒῭ᡂ㛗䚸Ⳙ 䛺ᝈ㈇ᢸ䚸ᘓ୰䜎䛯䛿ᵓ⠏୰䛾♫䛜䛒䜛䚹⤒῭ᡂ㛗䛾䜋䛛䚸▱ⓗ㈨ᮏ䜢䜰䝆䜰䛻ᡠ䛩㢌⬻䛾 ᦂ䜚ᡠ䛧䛻䜘䜚䚸ᆅᇦ䛾⛉Ꮫ䞉ᢏ⾡ⓗ䛺㊊ሙ䛿ᅛ䜑䜙䜜䛶䛝䛯䚹䛧䛛䛧䚸ᛴ㏿䛺ᡂ㛗䛸㇏䛛䛥䛻䜒䛛䛛䜟䜙䛪䚸 䜰䝆䜰䛾᭱๓⥺䛻䛿౫↛䛸䛧䛶ᣢ⥆ྍ⬟ᛶ䛸䛔䛖ၥ㢟䛜ṧ䛥䜜䛶䛔䜛䚹ᣢ⥆ྍ⬟ᛶ䛾ᮏ㉁䛿䚸♫ⓗṇ⩏ 䛸♫䛾Ᏻᐃ䛷䛒䜚䚸䛣䜜䛻䛿䚸㒔ᕷ㒊䛚䜘䜃㎰ᮧᆅᇦ䛻䛚䛡䜛䜘䜚Ⰻ䛔⏕ά᮲௳䛾ᩚഛ䜔䚸⏝ྍ⬟䛷 ᡭ䛤䜝䛺౯᱁䛾་⒪䛾ᥦ౪䛜క䛳䛶䛔䛺䛡䜜䜀䛺䜙䛺䛔䚹➃ⓗ䛻ゝ䛘䜀䚸ᚲせᛶ䚸䝜䜴䝝䜴䚸㈨※䚸䛚䜘䜃 㠉᪂䜈䛾ពᛮ䛜䚸䜰䝆䜰䛻䛿䛩䜉䛶Ꮡᅾ䛧䛶䛔䜛䚹ᡃ䚻䛿䚸䛣䛭ḟኚ䛸䛔䛖᪂䛧䛔┠ぬ䜑䛾ᐇ⌧䛻ྥ 䛡䛶❧䛱ୖ䛜䜚䚸䜰䝆䜰䛾⯆♫䛻䛚䛡䜛་⒪䝙䞊䝈䜢་⸆ရ⏘ᴗ䛻㞟⣙䛧䛶䛔䛛䛺䛡䜜䜀䛺䜙䛺䛔䚹 ㌴㍯䛸䝇䝫䞊䜽䛾䝰䝕䝹䜒ྠᵝ䛻䚸䛥䜙䛻ᗈ䛔ど㔝䛷ぢ䜛䛣䛸䛜䛷䛝䜛䚹ᚑ᮶䚸㻯㻾㻻䛿䚸༢䛺䜛ฟ᮶㧗ᡶ䛔䛾 䝃䞊䝡䝇ᥦ౪⪅䛸䛧䛶ᶵ⬟䛧䚸་⸆ရ⏘ᴗ䛾እഃ䛻⨨䛡䜙䜜䛶䛝䛯䚹䛧䛛䛧䚸䜰䝆䜰䛻䛚䛡䜛䝃䞊䝡䝇⏘ ᴗ䛿䚸་⸆ရ⏘ᴗ䛾ᩆ῭䛚䜘䜃ኚ㠉䛻䛚䛔䛶䛥䜙䛻䛝䛺ᙺ䜢ᢸ䛳䛶䛔䜛䚹䝃䞊䝡䝇⏘ᴗ䛿䚸་⸆ရ⏘ ᴗ䛻ᑐ䛩䜛ᗈ⠊䛛䛴ᶓ᩿ⓗ䛺ど㔝䛺䜙䜃䛻䜰䝆䜰䛻䛒䜛㝔䜔◊✲タ䛸䛾㛫䛷ᐦ᥋䛺㛵ಀ䜢⠏䛔䛶 䛚䜚䚸⯆୰䛾䜰䝆䜰䛻䛚䛔䛶䛿䚸䜘䜚Ⰻ䛔་⒪䜔䜘䜚Ⰻ䛔⸆䝥䝻䝉䝇䜢ᥦゝ䛩䜛୰❧ⓗᴗ⪅䛸䛺䜛䛣䛸 䛜䛷䛝䜛䚹䛣䜜䜢ᐇ⌧䛩䜛䛖䛘䛷䝃䞊䝡䝇ᴗ䛻ồ䜑䜙䜜䜛᭱䛾ྲྀ䜚⤌䜏䛿䚸⮬ᕫㄆ㆑䜢ኚ㠉䛩䜛䛣䛸䛷䛒䜛䚹 䛴䜎䜚䚸⮬㌟䜢་⸆ရ⏘ᴗ䛾䛚ᡭఏ䛔䛸⪃䛘䜛䛾䛷䛿䛺䛟䚸⯆୰䛾䜰䝆䜰䛻䛚䛡䜛䜘䜚Ⰻ䛔䝥䝻䝉䝇䛾ᥦゝ ⪅䛸⪃䛘䜛䛣䛸䛷䛒䜚䚸䛭䛾ሙྜ䚸ேᮦᩍ⫱䜔䜲䞁䝣䝷ᩚഛ䛻ᢞ㈨䜢䛩䜛ᚲせ䜒䛒䜝䛖䚹㻯㻾㻻⏘ᴗ䛻䛸䛳䛶䚸⮬ ㌟䜢䝃䞊䝡䝇ᥦ౪⪅䛸䛧䛶ぢ䜛䛾䛷䛿䛺䛟䚸䝋䝸䝳䞊䝅䝵䞁ᥦ౪⪅䛸ぢ䜛䛣䛸䛿䚸༢䛺䜛୍ḟኚ䛷䛧䛛䛺䛔䚹 ḟኚ䛿䚸㻯㻾㻻䛜⮬㌟䜢䜰䝆䜰䛻䛚䛡䜛䛂䛒䜛䜉䛝ጼ䛾᪂䛧䛔་⒪䛃䠄㻺㼑㼣㻌㻴㼑㼍㼘㼠㼔䠅䛾ຓ⏘፬䛸䛺䜛䛣䛸䛷䛒 䜛䚹⮫ᗋ◊✲䛻㛵䛩䜛ᑓ㛛ᢏ⾡䜔ᢞ㈨䜢୕ḟ་⒪㝔䛻䜒䛯䜙䛧䚸䜰䝆䜰䛾་⒪䝙䞊䝈䛻ᛂ䛘䜛⮫ᗋ㛤Ⓨ ィ⏬䜢స䜚䚸䛥䜙䛻䚸ᩚഛ୰䛷䛒䜛䜰䝆䜰䛾⸆ໃ䜢䚸་⒪䜢ᚲせ䛸䛧䛶䛔䜛ከ䛟䛾ே䛜ᜠᜨ䜢ཷ䛡䜙䜜䜛 䜘䛖䛻ᚋᢲ䛧䛧䛶䛔䛟䛣䛸䜒ᚲせ䛷䛒䜛䚹䛣䛾䛯䜑䛻䛿䚸䝃䞊䝡䝇⏘ᴗ⮬㌟䛜䚸䜰䝆䜰䛷⪃䛘䚸䜰䝆䜰䛻᰿ᕪ䛩 ᚲせ䛜䛒䜚䚸䛭䛖䛩䜛୰䛷䚸ᝈ⪅䜢་⒪䝅䝇䝔䝮䛾୰ᚰ䛻ྲྀ䜚ᡠ䛥䛺䛡䜜䜀䛺䜙䛺䛔䚹 䛣䛾䝥䝸䝈䝮䜢㏻䛧䛶ぢ䜛䛣䛸䚸䛂ᆅᇦ䜢⌮ゎ䛧䚸ᆅᇦ䛷⪃䛘䚸ᆅᇦ䛻᰿ᕪ䛩䛃䛸䛔䛖䝬䞁䝖䝷䜢㏻䛧䛶྾䛩䜛䛣 䛸䛷䚸〇⸆ᴗ䛾⨨䛛䜜䛶䛔䜛ᵓ㐀䝥䝺䞊䝖䛾䜚䛜䚸ᝏ䛔⤖ᯝ䜢䜒䛯䜙䛩ྍ⬟ᛶ䛿ప䛟䛺䜛䚹༴ᶵ䜢⾲䛩 ୰ᅜ䛾ゝⴥ䛂༴ᮘ䠄㼣㼑㼕㼖㼕䠅䛃䛜䚸༴㝤䛸ᶵ䜢୪ิ䛩䜛ㄒ䛸䛺䛳䛶䛔䜛䛾䛿䚸༢䛺䜛അ↛䛷䛿䛺䛔䜘䛖䛰䚹 www.quintiles.com 10 ⴭ⪅⤂ Amar Kureishi, 㻔䜰䝬䞊䝹䞉䜽䝺䜲䝅㻕 ་Ꮫ༤ኈ䚸㻲㻾㻯㻼㻯䠄㻲㼑㼘㼘㼛㼣㻌㼛㼒㻌㼠㼔㼑㻌㻾㼛㼥㼍㼘㻌㻯㼛㼘㼘㼑㼓㼑㻌㼛㼒㻌㻼㼔㼥㼟㼕㼏㼕㼍㼚㼟㻌㼍㼚㼐㻌㻿㼡㼞㼓㼑㼛㼚㼟㻌㼛㼒㻌㻯㼍㼚㼍㼐㼍㻚䠅㻌 䜽䜲䞁䝍䜲䝹䝈䚷䜰䝆䜰ᆅᇦ䝏䞊䝣䝯䝕䜱䜹䝹䜸䝣䜱䝃䞊ව་⸆ရ㛤Ⓨ㈐௵⪅㻌 䠄㻯㼔㼕㼑㼒㻌㻹㼑㼐㼕㼏㼍㼘㻌㻻㼒䟺㼏㼑㼞㻌㼍㼚㼐㻌㻴㼑㼍㼐㻌㼛㼒㻌㻰㼞㼡㼓㻌㻰㼑㼢㼑㼘㼛㼜㼙㼑㼚㼠㻘㻌㻽㼡㼕㼚㼠㼕㼘㼑㼟㻌㻭㼟㼕㼍䠅 㻰㼞㻚㻌㻭㼙㼍㼞㻌㻷㼡㼞㼑㼕㼟㼔㼕䛿䚸㻞㻜㻝㻜ᖺ㻤᭶䛻䜽䜲䞁䝍䜲䝹䝈䛻ຍ䜟䜚䚸䜰䝆䜰䛾ᡓ␎ⓗ་⸆ရ㛤Ⓨ䝴䝙䝑䝖䜢タ ❧䛧䛯䠄㻿㻰㻰㻌㻭㼟㼕㼍䠅䚹㻿㻰㻰㻌㻭㼟㼕㼍䛿䚸〇⸆ᴗ䛻䜘䜛〇ရ䛾⮫ᗋ㛤Ⓨ䜔⸆ᡓ␎䛾⟇ᐃ䜢ᨭ䛩䜛䛣䛸 䜢┠ⓗ䛸䛧䛶䛚䜚䚸ୡ⏺䛛䜙䛾ᨭᣢ䜢ᛴ㏿䛻ቑ䜔䛧䚸タ❧ึᖺᗘ䛻䚸㢳ᐈᴗ㻝㻜♫䛻ᑐ䛧䛶䚸㻝㻡✀㢮䛾 ྜ≀䛻㛵䛩䜛䜰䝆䜰ᡓ␎䛾⪃䜢䝃䝫䞊䝖䛧䛯䚹 䜽䜲䞁䝍䜲䝹䝈䛻ཧ⏬䛩䜛௨๓䛾㻰㼞㻚㻌㻷㼡㼞㼑㼕㼟㼔㼕䛿䚸䝞䜲䜶䝹♫䛻䛚䛔䛶⸆㒊㛛䛾䜾䝻䞊䝞䝹㈐௵⪅䛷 䛒䜚䚸ୡ⏺୰䛾䝞䜲䜶䝹䞉䝦䝹䝇䜿䜰䛻䛚䛔䛶⒪㡿ᇦయ䜢⤫ᣓ䛧䛶䛔䛯䚹㻰㼞㻚㻌㻷㼡㼞㼑㼕㼟㼔㼕䛿䚸䝞䜲䜶䝹 ♫䛻䛚䛡䜛㻝㻝ᖺ㛫䛾⫋Ṕ䛾୰䛷䚸⡿ᅜ䚸䝗䜲䝒䚸୰ᅜ䚸䝅䞁䜺䝫䞊䝹䜈䛾㓄ᒓ䜢ྵ䜑䚸ከᵝ䛺ᆅᇦ䛷ά ㌍䛧䚸ୖ⣭⟶⌮⪅䛸䛧䛶䛾ᆅ䜢⠏䛔䛶䛔䛳䛯䚹㻞㻜㻜㻡ᖺ䚸䝞䜲䝇䝥䝺䝆䝕䞁䝖ව䜰䝆䜰ኴᖹὒᢸᙜ䛾⮫ ᗋ㛤Ⓨ䛚䜘䜃⸆㈐௵⪅䛸䛧䛶୰ᅜ䛻㓄ᒓ䛸䛺䜚䚸୰ᅜ䛚䜘䜃䜰䝆䜰ኴᖹὒ䛻䛚䛔䛶䝞䜲䜶䝹♫䛾⮫ ᗋ㛤Ⓨ⬟ຊ䛚䜘䜃䜲䞁䝣䝷䜢ᵓ⠏䛩䜛ᶒ㝈䜢䛘䜙䜜䛯䚹⤖ᯝ䛸䛧䛶䚸䝛䜽䝃䝞䞊䝹䜔䝄䝺䝹䝖䛺䛹䛾〇 ရ㛤Ⓨ䛜ຍ㏿䛥䜜䛯䚹 㻰㼞㻚㻌㻷㼡㼞㼑㼕㼟㼔㼕䛿་ᖌ䛷䛒䜚ឤᰁ䛾ᑓ㛛ᐙ䛷䛒䜛䚹䜹䝘䝎䚸䜶䝗䝰䞁䝖䞁䛾䜰䝹䝞䞊䝍Ꮫ䛷་ᏛᏛ 䜢ྲྀᚓ䚹㻾㼛㼥㼍㼘㻌㻯㼛㼘㼘㼑㼓㼑㻌㼛㼒㻌㻼㼔㼥㼟㼕㼏㼕㼍㼚㼟㻌㼍㼚㼐㻌㻿㼡㼞㼓㼑㼛㼚㼟㻌㼛㼒㻌㻯㼍㼚㼍㼐㼍䛾≉ู◊✲ဨ䛷䛒䜚䚸㻵㻺㻿㻱㻭㻰䛾༞ᴗ ⏕䛷䜒䛒䜛䚹⏘ᴗ⏺䛷ά㌍䛩䜛௨๓䛿䚸䜹䝘䝎䛾䜹䝹䜺䝸䞊Ꮫ䛾ᩍᤵ䛷䛒䜚䚸㻢㻜௨ୖ䛾グ䜔ᢒ 㘓䜢ᇳ➹䛧䛯䚹㻰㼞㻚㻌㻷㼡㼞㼑㼕㼟㼔㼕䛿䚸๓ᅇ䛾ⓑ᭩䛂䜰䝆䜰㻦㻌ᡓ␎ⓗ་⸆ရ㛤Ⓨ䛾᪂䛧䛔䝣䝻䞁䝔䜱䜰䛃䛻䛚䛔 䛶䚸ぢ㆑㠃䛷䛾䝸䞊䝎䞊䝅䝑䝥䠄㼀㼔㼛㼡㼓㼔㼠㻌㻸㼑㼍㼐㼑㼞㼟㼔㼕㼜䠅䜢☜❧䛧䛯䚹䛣䛾ⓑ᭩䛻䛚䛔䛶䚸䜰䝆䜰䛷䛾་⸆ ရ㛤Ⓨ䛻ᚲせ䛺䜒䛾䛸䛧䛶䚸༠ㄪⓗ䛺」ᩘ䛾䜰䝷䜲䜰䞁䝇䛷䛒䜛䛂㌴㍯䛸䝇䝫䞊䜽䛃䝰䝕䝹䜢ᥦ䛧䛯䚹䛣 䛾䝰䝕䝹䛿䚸㻿㻰㻰㻌㻭㼟㼕㼍䛜ྲྀ䜚⤌䜣䛷䛔䜛୍䛴䛾䛷䛒䜛䚹 11 www.quintiles.com Contact Us: On the web: www.quintiles.com Email: [email protected] Copyright © 2012 Quintiles. 01.15.22-072012 Whitepaper, Tectonic Transformations: The Future of Biopharmaceuticals in Asia
© Copyright 2024 Paperzz
